US 2010/0062078 A1 · PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND THE SIGNALING PATHWAY THEREOF

Abstract

A pharmaceutical composition, composed of protoapigenone (formula I), for treating gynecological cancers, prostate cancer, urinary bladder cancer and hepatocarcinoma is provided. Protoapigenone has cytotoxicity on these cancers, and arrests the cell cycle at S and G2/M phases. In addition, protoapigenone regulates cell signaling pathways, such as caspase-3, PARP, p-38 MAPK and JNK½, to induce apoptosis. Protoapigenone significantly inhibits the xenograft tumor growth on nude mice, without major side effects. Co-treatment o protoapigenone of protoapigenone and cisplatin shows synergistic cytotoxicity of MDAH-2774 ovarian cancer cells.

Claims19

Dependent claims

A pharmaceutical composition for treating a cancer, comprising a flavonoid represented by formula I:

wherein the cancer is one selected from a group consisting of a gynecological cancer, a prostate cancer, a bladder cancer and a liver cancer.

Dependencies are inferred from the claim text.

Facts

Application

12/399,155Filed 6 Mar 2009

Priority

TW 0971342875 Sep 2008

Published

11 Mar 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/353
Condensed with carbocyclic rings, e.g. methantheline: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 33/243
Heavy metals; Compounds thereof: platinum; Compounds thereof
A61K 36/11
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g.…:…
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Pharmaceutical composition for treating cancer and the signaling pathway thereof

Life of this patent

Pharmaceutical composition for treating cancer and the signaling pathway thereof

Life of this patent

Abstract

Claims19